Patient Access Quotes

My own medical history during my hospital stay was readily available to me through literally thousands of pages of medical records that outlined everything from my 'bowel releasing' schedule to the minute details of my brain biopsy procedure.

Named after four activists and their families who fought for its passage, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 establishes a new pathway for access to unapproved, investigational treatments. These four Americans fought for the Right to Try because they didn't want to give up.

Affordability is critical so that patients have access to medicines. At the same time, it's also important that we have the kind of incentives that allow us to do the kinds of studies that we need to do to go after these diseases like Alzheimer's.

Congress should let HRSA release its guidance and analyze its impact before making changes to the 340B program that would harm safety-net hospitals and our vulnerable patients.

Every insurer must offer every individual a plan and ensure each patient with pre-existing conditions has access to 'adequate and affordable health insurance coverage.'

Our interaction as patients with the NHS should be on the basis that there's a presumption that all information is shared with us.

Over the years, HIV/AIDS activists and their allies have been pioneers in creating new frontiers in the medical establishment. Through their efforts, the FDA drug approval procedures were reformed so promising new therapies could reach desperate patients quicker.

The way we have looked at pricing at Merck is we've always said we want to be responsible, which means we want to optimize profitability and patient access.

As a practicing physician for over 30 years, I can assure the president that the majority of physicians in this country are for health-care reform - just not the government-run reform he prefers.

Most drugs sold in the U.S. are produced outside of the country, and if we can ensure supply-chain safety for these drugs, introducing more of them to the market quicker could mean major differences in the price of drugs, quality of life for patients, and for some Americans the difference between life and death.

In order for America to remain the leader in medical innovation, we must reduce costs, ease regulatory burdens, and increase the efficacy of producing new treatments and cures here in the U.S.

Patients who face long odds and terminal illnesses do not always have access to the latest drugs in clinical trials. They don't want to give up, but they don't have years to wait for new drugs to receive FDA approval.

To improve global health, it's not enough just to have a really good new product and to obtain marketing approval. You still need to market the product and bring it to patients, follow up, create the infrastructure, and so on - the whole pipeline, the network. That's something that companies are extremely good at: organizing a whole pipeline in a cost-effective way.